WHEAT RIDGE, CO -- (MARKET WIRE) -- 06/07/07 -- GeneThera, Inc. (OTCBB: GTHA) has developed a method to quantitate the expression of the Erythroid Differentiation-Related Factor (EDRF) gene capable of detecting the presence of Mad Cow Disease in the blood of infected animals. The current testing model to diagnose Mad Cow Disease relies on postmortem testing to detect the presence of infectious prion proteins in the brain. GeneThera has developed a method for detection of Mad Cow Disease in the blood of live animals without the need of a postmortem test.

GeneThera is currently in the process of building the lab in Italy and will have the lab open on January 7, 2008 to begin operations.

The expected goals of GeneThera's Italian Operations are: (1) to establish validation protocols to compare GeneThera live animal blood test technology for the detection of Mad Cow Disease to current available methodologies for the "post mortem detection," (2) to establish a research protocol for a time course correlation study between the effected EDRF gene expression levels in blood and the presence of Mad Cow Disease in live, experimentally infected, animals, (3) to establish a screening program, using GeneThera's live animal blood test system, for large scale cattle testing in feedlots and slaughter houses, and (4) to establish an animal model for vaccine and assay development using experimentally infected animals.

The costs for the Italian operations for the next 12 months are $700,000. The costs include $250,000 for the equipment and $450,000 for the continued operations. GeneThera will not generate any revenue from its Italian operations. However, GeneThera expects to generate revenue once its protocol for Mad Cow Disease has been validated. GeneThera expects to market its test to foreign countries and within the United States once the USDA ban on testing is lifted.

ABOUT GENETHERA, INC.:

GeneThera, Inc. is a biotechnology company that develops molecular testing and DNA vaccines for animal diseases that may cause diseases in humans. The core of its operation is the ongoing development of molecular diagnostic assays using Real Time Fluorogenic Polymerase Chain Reaction (F-PCR) technologies to detect the presence of infectious disease from the blood of animals, particularly, live animals.

Application of the Safe Harbor of the Private Securities Litigation Reform Act of 1995:

This press release contains, and GeneThera may from time to time make, written or oral "forward-looking statements" within the meaning of the U.S. federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and other factors, many of which are outside GeneThera's control that could cause actual results to differ materially from such statements. In particular, statements using words such as "may," "should," "estimate," "expect," "anticipate," "intend," "believe," "predict," "potential," or words of similar import generally involve forward-looking statements.

Contact:

GeneThera, Inc.
Dr. Tony Milici
CEO
(303) 463-6371
http://www.genethera.net

The Mezey Howarth Group
J. Wade Mezey/Paul Howarth
Genethera@mezeyhowarth.com
(949) 429-4007